Braidwell »

Celcuity shares owned by Braidwell

Quarter-by-quarter ownership of Celcuity (CELC) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Celcuity

Tip: Access up to 7 years of quarterly data

All positions including Celcuity held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Celcuity by Braidwell

Quarter filed Position value Share count Share price at filing
2024-09-30 $13M 884k 14.91
2024-06-30 $8.5M 517k 16.38

More positions owned by Braidwell

Guardant Health Note11/1 (Principal)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Novocure Note11/0 (Principal)
Cg Oncology (CGON)
Nuvasive Note 0.375% 3/1 (Principal)
Xenon Pharmaceuticals (XENE)
Neurocrine Biosciences (NBIX)
Neogenomics Note 0.250% 1/1 (Principal)
Apogee Therapeutics (APGE)
Apellis Pharmaceuticals (APLS)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Dexcom Note 0.375% 5/1 (Principal)
Align Technology (ALGN)
Guardant Health (GH)
Insulet Corp Note 0.375% 9/0 (Principal)

View all positions for Braidwell

Top funds holding Celcuity

BVF
Morgan Stanley
Perceptive Advisors
Baker Bros. Advisors
BlackRock
Vanguard Group
Eventide Asset Management
Commodore Capital
BlackRock
Samlyn Capital
NEA Management Company
Soleus Capital Management
Balyasny Asset Management
Braidwell
Citadel Advisors

View all funds holding Celcuity